Literature DB >> 11053420

Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes.

B C Lutters1, J C Meijers, R H Derksen, J Arnout, P G de Groot.   

Abstract

Anti-beta(2)-glycoprotein I antibodies are thought to cause lupus anticoagulant activity by forming bivalent complexes with beta(2)-glycoprotein I (beta(2)GPI). To test this hypothesis, chimeric fusion proteins were constructed of the dimerization domain (apple 4) of factor XI and beta(2)GPI. Both a covalent (apple 4-beta(2)GPI) and a noncovalent (apple 4-C321S-beta(2)GPI) chimer were constructed. As controls, apple 2-beta(2)GPI and apple 4-C321S-beta(2)GPI-W316S, in which beta(2)GPI-W316S is not able to bind to phospholipids, were made. In a phospholipid binding assay, apple 4-beta(2)GPI and apple 4-C321S-beta(2)GPI were able to bind to phospholipids with an affinity 35 times higher than that of plasma-derived beta(2)GPI and apple 2-beta(2)GPI. Apple 4-C321S-beta(2)GPI-W316S did not bind at all. Only apple 4-beta(2)GPI and apple 4-C321S-beta(2)GPI were able to bind to adhered platelets as shown by immunofluorescence. Using the prothrombin time, which was the most responsive coagulation assay, the clotting time was approximately doubled when 200 microg/ml apple 4-beta(2)GPI or apple 4-C321S-beta(2)GPI was added. Addition of 200 microg/ml plasma-derived beta(2)GPI, apple 2-beta(2)GPI, or apple 4-C321S-beta(2)GPI-W316S did not affect clotting time. Clotting time could be corrected with the addition of extra phospholipids, which is indicative for lupus anticoagulant activity. An additional increase in clotting times for apple 4-beta(2)GPI or apple 4-C321S-beta(2)GPI was achieved by the addition of monoclonal antibodies against beta(2)GPI. In conclusion, dimerization of beta(2)GPI explains the in vitro observed effects of beta(2)GPI-anti-beta(2)GPI antibody complexes.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053420     DOI： 10.1074/jbc.M008224200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  15 in total

1.  Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I bα.

Authors:  Wenjing Zhang; Fei Gao; Donghe Lu; Na Sun; Xiaoxue Yin; Meili Jin; Yanhong Liu
Journal:  Front Med       Date:  2015-11-30       Impact factor: 4.592

2.  Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study.

Authors:  Roland Gamsjaeger; Alexander Johs; Anna Gries; Hermann J Gruber; Christoph Romanin; Ruth Prassl; Peter Hinterdorfer
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

Review 3.  Pathogenic role of antiphospholipid antibodies.

Authors:  J E Salmon; P G de Groot
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

Review 4.  The significance and management of thrombocytopenia in antiphospholipid syndrome.

Authors:  Bahar Artim-Esen; Reyhan Diz-Küçükkaya; Murat İnanç
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9.

Authors:  Arnaud Dupuy D'Angeac; Ilias Stefas; Hubert Graafland; Frédéric De Lamotte; Marcel Rucheton; Caroline Palais; Anna-Karin Eriksson; Priscille Bosc; Caroline Rosé; Robert Chicheportiche
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

6.  Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).

Authors:  Tara C White-Adams; Michelle A Berny; Erik I Tucker; Jacqueline M Gertz; David Gailani; Rolf T Urbanus; Philip G de Groot; András Gruber; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

7.  Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome.

Authors:  Zurina Romay-Penabad; Renan Aguilar-Valenzuela; Rolf T Urbanus; Ronald H W M Derksen; Maarten T T Pennings; Elizabeth Papalardo; Tuya Shilagard; Gracie Vargas; Yong Hwang; Philip G de Groot; Silvia S Pierangeli
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

Review 8.  Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.

Authors:  Joyce Rauch; Paolo D'Agnillo; Rebecca Subang; Jerrold S Levine
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

9.  Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets.

Authors:  Edouard M Bevers; Marie P Janssen; Paul Comfurius; Krishnakumar Balasubramanian; Alan J Schroit; Robert F A Zwaal; George M Willems
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

10.  Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome.

Authors:  Y Shoenfeld; I Krause; F Kvapil; J Sulkes; S Lev; P von Landenberg; J Font; J Zaech; R Cervera; J C Piette; M C Boffa; M A Khamashta; M L Bertolaccini; G R V Hughes; P Youinou; P L Meroni; V Pengo; J D Alves; A Tincani; G Szegedi; G Lakos; G Sturfelt; A Jönsen; T Koike; M Sanmarco; A Ruffatti; Z Ulcova-Gallova; S Praprotnik; B Rozman; M Lorber; V B Vriezman; M Blank
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.